Next Science Ltd
ASX:NXS
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
AU |
Next Science Ltd
ASX:NXS
|
72.9m AUD | -5.2 | ||
CH |
Alcon AG
SIX:ALC
|
41B CHF | 84.6 | ||
JP |
Hoya Corp
TSE:7741
|
6.6T JPY | 41 | ||
DK |
Coloplast A/S
CSE:COLO B
|
194.5B DKK | 73.6 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
19B USD | 31.2 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.8B USD | 80.4 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
58.4B CNY | 51.7 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.2B GBP | 38.5 | ||
CH |
Ypsomed Holding AG
SIX:YPSN
|
5.3B CHF | -611.5 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.7B USD | 26 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.5B USD | 26.8 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.